.png){kind=icon}
.png){kind=icon}
Return
Physiologically Based Pharmacokinetic Modeling of Elexacaftor/Tezacaftor/Ivacaftor in Infants With Cystic Fibrosis
.png){kind=icon}
OA
AI
N
S
N
E
A
P
M
P
L
S
M
G
S
J
I
F
M
DOI：10.1002/psp4.70225.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Ivacaftor is the only cystic fibrosis transmembrane conductance regulator modulator approved for infants ≥ 1 month. The elexacaftor/tezacaftor/ivacaftor combination, approved for children aged ≥ 2 years, has been shown to significantly slow CF progression. Expanding elexacaftor/tezacaftor/ivacaftor use to infants may offer additional therapeutic benefits. This study aims to predict elexacaftor/tezacaftor/ivacaftor pharmacokinetics in infants aged 1 month to < 2 years using physiologically based pharmacokinetic modeling (PBPK) and to determine whether age- and weight elexacaftor/tezacaftor/ivacaftor doses, extrapolated from ivacaftor monotherapy, produce drug exposures comparable to adult levels. Adult elexacaftor/tezacaftor/ivacaftor PBPK published models were first reproduced using Simcyp. These models were scaled to children aged 2–18 years via the Simcyp Pediatric Simulator and the Uprety–Wahlström cytochrome-P450 3A4 ontogeny method to simulate the current elexacaftor/tezacaftor/ivacaftor dosing regimen. FDA-approved ivacaftor monotherapy dosing was evaluated in children 1 month to < 2 years and subsequently used to guide the extrapolation of elexacaftor/tezacaftor/ivacaftor combination dosing regimens. The overall workflow was validated using in vivo pharmacokinetic data or literature-based sources. Elexacaftor/tezacaftor/ivacaftor PBPK models for adults and children ≥ 2 years were validated against observed clinical pharmacokinetic data. Simulations of elexacaftor/tezacaftor/ivacaftor doses based on ivacaftor monotherapy in infants < 2 years matched adult-reported levels, except in infants 1–2 months, who showed lower exposures, and in those weighing ≥ 14 kg, who may experience higher exposures. Using PBPK modeling, supported by clinical pharmacokinetic data, this study explores elexacaftor/tezacaftor/ivacaftor dosing in children under 2 years. The findings offer preliminary dosing guidance, pending confirmation in larger clinical studies, with therapeutic drug monitoring recommended to guide treatment.
Keywords:
CFTR modulators
cystic fibrosis
infants
PBPK
therapeutic drug monitoring
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
C
IF:
0
Papers:
73
Citations:
0
Organization
Cited Papers